Advanced Atrial Fibrillation Nursing

AF Classification

🗂️Five AF Types (ESC 2020)

Type	Definition
First Detected	First documented episode — regardless of duration or symptoms
Paroxysmal	Self-terminating, usually <48 h (always <7 days)
Persistent	Sustained >7 days; requires cardioversion to terminate
Long-Standing Persistent	Continuous AF >12 months; rhythm control still considered
Permanent	AF accepted by patient & clinician — rate control only strategy

📊4-S-AF Scheme — Structured Characterisation

Stroke risk — CHA₂DS₂-VASc score → anticoagulation decision
Symptom burden — EHRA symptom class (I–IV): I = no symptoms → IV = disabling symptoms
Severity of AF burden — AF type, duration, frequency of episodes, Holter burden %
Substrate severity — comorbidities, structural heart disease, LA size, diastolic dysfunction

All four domains must be characterised to individualise AF management.

ECG Recognition

📈12-Lead ECG Features of AF

Irregular R-R intervals ─── no discrete P waves ─── fibrillatory baseline (f-waves 350-600/min) Ventricular rate: 100-180 bpm (uncontrolled) │ Narrow QRS (unless aberrant conduction/BBB) f-waves best seen: V1, II, III, aVF │ Variable amplitude & morphology

Key ECG Criteria

Irregularly irregular RR intervals (cardinal feature)
Absence of distinct P waves
Fibrillatory baseline 350–600 impulses/min
Ventricular rate 100–180/min if uncontrolled
QRS usually narrow (<120 ms) unless aberrancy

Differentiate From

Atrial flutter — regular sawtooth at 300/min, regular or fixed RR
MAT — ≥3 distinct P-wave morphologies, irregular but P waves present
Frequent PACs — irregular but P waves visible
AF + WPW — wide complex, irregular, can degenerate to VF → do NOT give AV-nodal drugs

Haemodynamic Assessment

✅Haemodynamically Stable AF

BP ≥90/60 mmHg, no signs of shock
No acute chest pain / ischaemia
No acute pulmonary oedema
Conscious, maintaining SpO₂
HR controlled or tolerated

Action: Rate control, anticoagulation assessment, elective cardioversion if appropriate

🚨Haemodynamically UNSTABLE AF

Hypotension: SBP <90 mmHg
Chest pain / ongoing ischaemia
Acute pulmonary oedema / flash APO
Syncope or reduced consciousness
Severe end-organ hypoperfusion

Action: Immediate synchronised DC cardioversion — do NOT delay for anticoagulation in emergency. Anticoagulate post-DCCV.

Common Precipitants — PIRATES Mnemonic

🏴‍☠️PIRATES — Precipitants of AF

P — Pulmonary disease (PE, pneumonia, COPD exacerbation)

I — Infection / Ischaemia (ACS, myocarditis)

R — Rheumatic heart disease / valvular disease

A — Anaemia / electrolyte disturbance (hypokalaemia, hypomagnesaemia)

T — Thyroid (hyperthyroidism — check TSH in new AF)

E — Elevated BP (hypertension — #1 cause in GCC)

S — Sepsis / post-surgical

Holter Monitoring — Nursing Role

⌚Ambulatory ECG Monitoring

Indications

Suspected paroxysmal AF (palpitations, unexplained syncope)
Post-cryptogenic stroke — AF detection
Monitoring AF burden pre/post ablation
Assessing rate control adequacy

Nursing Instructions to Patient

Keep diary: log symptoms with time
Avoid prolonged contact with magnets / MRI
No shower while wearing leads (sponge bath only)
Press event marker during symptoms
Continue normal daily activities
Return device as instructed (24 h / 48 h / 7 days / 14 days)

CHA₂DS₂-VASc Score

🧮CHA₂DS₂-VASc Criteria

Criterion	Points	Notes
C — Congestive Heart Failure / LV dysfunction	+1	EF <40% or recent decompensation
H — Hypertension	+1	On treatment or BP >140/90
A₂ — Age ≥ 75 years	+2	Doubled weight — strongest independent predictor
D — Diabetes mellitus	+1	On medication or fasting glucose >7 mmol/L
S₂ — Stroke / TIA / Thromboembolism history	+2	Prior stroke doubles risk
V — Vascular disease (MI, PAD, aortic plaque)	+1	Documented vascular disease
A — Age 65–74 years	+1	Separate from A₂ above
Sc — Sex category (female)	+1	Female sex is a risk modifier, not standalone — only adds value if ≥1 other risk factor

Score 0 (male) / 0 (female)
No anticoagulation needed. Low risk.

Score 1 (male)
Consider anticoagulation. Assess individually. Prefer DOAC if initiated.

Score ≥2 (male) / ≥3 (female)
Anticoagulation recommended. DOAC preferred over warfarin (unless MS/mechanical valve).

HAS-BLED Bleeding Risk

🩸HAS-BLED Score

Criterion	Points	Modifiable?
H — Hypertension (SBP >160 mmHg)	+1	Yes — treat BP
A — Abnormal renal function (dialysis, creatinine >200 µmol/L) or liver (cirrhosis, bilirubin >2×)	+1 or +2	Partially
S — Stroke history	+1	No
B — Bleeding history or predisposition	+1	Yes — investigate & treat
L — Labile INR (TTR <60% on warfarin)	+1	Yes — switch to DOAC
E — Elderly (age >65)	+1	No
D — Drugs (antiplatelets, NSAIDs) or alcohol (>8 units/week)	+1 or +2	Yes — review medications

Score ≥3 = High bleeding risk. HIGH HAS-BLED does NOT justify withholding anticoagulation. Identify and correct modifiable bleeding risk factors. Document and reassess regularly.

DOACs vs Warfarin

💊Anticoagulant Comparison

Agent	Mechanism	Dosing	Renal Adj.	Reversal
Apixaban	Factor Xa inhibitor	5 mg BD (2.5 mg BD if ≥2 of: age ≥80, weight ≤60 kg, Cr ≥133)	Reduce if criteria met	Andexanet alfa
Rivaroxaban	Factor Xa inhibitor	20 mg OD with evening meal (15 mg OD if CrCl 15–49)	CrCl <15 — avoid	Andexanet alfa
Edoxaban	Factor Xa inhibitor	60 mg OD (30 mg if CrCl 15–50, weight ≤60 kg, or P-gp inhibitor)	Reduce if criteria	Andexanet alfa
Dabigatran	Direct thrombin inhibitor	150 mg BD (110 mg BD if age ≥80, or age ≥75 + high bleed risk)	CrCl <30 — avoid	Idarucizumab (specific)
Warfarin	Vitamin K antagonist	Individualised — target INR 2–3	Not adjusted by renal	Vitamin K / 4-F PCC / FFP

DOAC Advantages

Fixed dosing — no routine INR monitoring
Fewer food interactions
Rapid onset / offset
Superior or non-inferior to warfarin in trials
Lower intracranial haemorrhage risk

Warfarin Still Preferred In

Mechanical heart valves
Moderate–severe mitral stenosis
CrCl <15 mL/min (most DOACs)
Antiphospholipid syndrome (triple positive)
Resource-limited settings with INR monitoring available

Warfarin Nursing Management

📋Warfarin — Key Nursing Points

Target INR 2.0–3.0 for non-valvular AF; 2.5–3.5 for mechanical mitral valve
INR checks: weekly when initiating → monthly when stable
Bridging therapy (LMWH) when INR sub-therapeutic and high stroke risk
Document Time in Therapeutic Range (TTR) — target >70%
Educate on consistent vitamin K intake (do not avoid; be consistent)

Warfarin Reversal

INR 4–10, no bleeding: hold dose ± oral vitamin K 1–2 mg
INR >10, no bleeding: hold + oral vitamin K 2–5 mg
Major bleeding: 4-factor PCC (Beriplex/Octaplex) + IV vitamin K 5–10 mg
Life-threatening bleeding: 4-F PCC immediately — do not wait for INR

Interactive CHA₂DS₂-VASc & HAS-BLED Calculator

🔬DOAC Renal Dose Adjustment Helper

Enter the patient's creatinine clearance (CrCl) in mL/min to receive dosing guidance:

Rate Control Strategy

❤️Heart Rate Targets

Lenient Rate Control: HR <110 bpm (resting)
Acceptable for most asymptomatic patients. RACE II trial supports this approach.

Strict Rate Control: HR <80 bpm (resting)
Consider if symptomatic despite lenient control or tachycardia-induced cardiomyopathy suspected.

💊Rate Control Agents

Drug Class	Examples	Dosing Notes	Cautions
Beta-blockers1st line	Bisoprolol, Metoprolol, Carvedilol	Bisoprolol 1.25–10 mg OD; Metoprolol 25–100 mg BD	Avoid in acute decompensated HF, severe bradycardia, 2nd/3rd degree AVB without pacemaker, severe reactive airways
Rate-limiting CCBs	Diltiazem, Verapamil	Diltiazem 60–120 mg TDS; Verapamil 40–120 mg TDS	AVOID in HFrEF (EF <40%) — negative inotropy. Do not combine with beta-blocker routinely.
Digoxin	Digoxin (Lanoxin)	Loading: 0.5 mg IV or 1 mg PO in divided doses over 24 h Maintenance: 62.5–250 mcg OD (renal adjusted)	Therapeutic level: 0.5–2 ng/mL (aim 0.5–0.9 ng/mL in HF). Toxicity: nausea, visual changes, bradycardia, arrhythmias
Amiodarone	Amiodarone	IV loading if acute; oral 200 mg OD maintenance	Use as last resort for rate control; multiple organ toxicities (thyroid/lung/liver). Monitor TFT, LFT, CXR every 6 months.

Digoxin Toxicity — Nursing Monitoring

Signs of Digoxin Toxicity

GI: nausea, vomiting, anorexia, abdominal pain
Visual: yellow-green halos, blurred vision
Cardiac: bradycardia, heart block, VT (bidirectional VT pathognomonic)
CNS: confusion, fatigue, headache

Nursing Actions

Check apical pulse 1 min before giving — withhold if HR <60 bpm and notify
Monitor serum digoxin, K⁺, Mg²⁺, renal function
Hypokalaemia potentiates toxicity — correct electrolytes
Digoxin immune Fab (Digibind) for life-threatening toxicity
Continuous ECG monitoring during IV loading

Rhythm Control Strategy

⚡When to Consider Rhythm Control

Symptomatic despite adequate rate control (EHRA ≥II)
First detected or early persistent AF (<12 months)
Younger patients with minimal comorbidities
Tachycardia-mediated cardiomyopathy
Patient preference after counselling
AF with WPW syndrome — first-line

EAST-AFNET 4 Trial: Early rhythm control within 1 year of AF diagnosis reduced cardiovascular death, stroke, and HF hospitalisation compared to rate control alone. Rhythm control now preferred in symptomatic early AF.

🧪Chemical Cardioversion — Antiarrhythmic Drugs

Drug	Use	Dose	Key Monitoring
Flecainide	Paroxysmal AF, no structural heart disease Pill in pocket strategy	200–300 mg PO single dose; or IV 2 mg/kg over 10 min	ECG (QRS widening >25% → stop), QTc, contraindicated in SHD, LV dysfunction, or CAD
Amiodarone	Structural heart disease, HFrEF — preferred AAD	IV: 300 mg in 250 mL D5W over 20–60 min, then 900 mg/24 h Oral: 600 mg/day ×4 weeks → 200 mg OD maintenance	TFT (hypo/hyperthyroidism), LFT, CXR (pulmonary toxicity), corneal microdeposits, photosensitivity. Monitor every 6 months.
Propafenone	Paroxysmal AF, no SHD	450–600 mg PO single dose	ECG monitoring, avoid in SHD / HF

🔥AF Catheter Ablation — Pulmonary Vein Isolation

Pre-procedure Nursing

TOE / CT scan to exclude LA thrombus (if not on OAC for ≥3 weeks)
Continue anticoagulation peri-procedurally (uninterrupted preferred)
Fasting 4–6 hours before procedure
Baseline ECG, U&E, FBC, coagulation screen
Patient education: expected duration 2–4 hours, groin access

Post-procedure Nursing

Groin access site: compression 4–6 h, check for haematoma/bleeding
Continuous ECG monitoring for arrhythmia recurrence (blanking period: first 3 months)
Fluid balance — oesophageal-pericardial fistula risk (rare but fatal)
Watch for phrenic nerve palsy (hiccups, dyspnoea)
Pericardial tamponade — watch for hypotension, JVD, muffled sounds (emergency pericardiocentesis)
Continue anticoagulation for minimum 3 months post-ablation
Warn: AF recurrence common in first 3 months — does not indicate failure

Pre-DCCV Checklist

✅Pre-Cardioversion Nursing Checklist

Anticoagulation Criteria

Therapeutic anticoagulation ≥3 consecutive weeks (INR 2–3 for warfarin; adherence confirmed for DOAC)
OR TOE performed within 24–48 h excluding LA/LAA thrombus
DOAC confirmed taken — last dose timing documented
Anticoagulation to continue for minimum 4 weeks post-DCCV (stunned atrium)

Clinical Checks

Written informed consent obtained
Fasting ≥4 hours (solids); 2 h (clear fluids)
Large-bore IV access (18G or larger) patent
12-lead ECG confirming AF — document
Electrolytes checked (K⁺ ≥3.5 mmol/L, Mg²⁺ normal)
Digoxin level if on digoxin — not toxic
Thyroid function known (hyperthyroid AF has low success rate)
Pregnancy excluded in women of childbearing age

🛠️Equipment Preparation

Defibrillator

Biphasic defibrillator confirmed functional
SYNC mode activated — check sync spike on R-wave
Anterior-posterior pad positioning preferred (better transthoracic impedance)
Gel pads applied correctly
Energy: 150–200 J biphasic (start at 200 J)

Emergency Equipment

Crash trolley at bedside — ALS drugs, pacing capability
Airway: BVM, suction, laryngoscope, ETT
Oxygen with non-rebreather mask
SpO₂ probe applied before sedation
NIBP cuff and continuous ECG monitor leads

Team

Cardiologist / physician performing DCCV
Anaesthetist or sedation-trained physician
Minimum 2 nurses: one monitoring, one assisting
Document time-out completed

Sedation Protocol

💉Conscious Sedation for DCCV

Option 1: Midazolam + Fentanyl

Fentanyl 1–2 mcg/kg IV (analgesia) then Midazolam 0.05–0.1 mg/kg IV titrated to sedation
Onset 2–3 min; recovery 20–40 min
Reversal: Flumazenil (midazolam) + Naloxone (fentanyl)
Suitable when anaesthesia service available

Option 2: Propofol (Anaesthetist Only)

Propofol 1–2 mg/kg IV — rapid onset, excellent amnesia
Risk: apnoea, hypotension — anaesthetist present mandatory
Recovery rapid (5–10 min consciousness regained)
No specific reversal agent — supportive care

Nursing Sedation Monitoring: continuous SpO₂, ETCO₂ if available, respiratory rate, level of consciousness (RASS), BP every 3 minutes during procedure.

DCCV Procedure

⚡Step-by-Step DCCV

Confirm SYNC mode is ON — verify sync marker on each R-wave on monitor. If not synchronised → risk of R-on-T → ventricular fibrillation.

Select energy: Start 200 J biphasic (anterior-posterior) or 150 J (anterior-lateral). Escalate if unsuccessful.

Sedation administered. Wait until patient is adequately sedated (no response to verbal stimulation).

Clear the patient — "I'm clear, you're clear, everyone clear!" Oxygen mask removed ≥1 m from patient. All personnel stand clear.

Deliver shock. Machine will deliver at R-wave — slight delay is normal in SYNC mode. Do not move paddles.

Immediately assess rhythm — document ECG. If AF persists → re-escalate energy → repeat. Maximum 3 attempts.

Post-shock: reassess rhythm, BP, airway, consciousness. Document time, energy used, outcome.

Post-DCCV Nursing Care

🔍Post-Cardioversion Monitoring

Monitoring Protocol

Continuous ECG monitoring for minimum 1–2 hours
12-lead ECG once sinus rhythm established
BP every 15 min × 4, then 30 min × 2 until discharge
SpO₂ continuous until fully awake
Skin checks at pad sites — erythema/burn (treat with cool compress)
Neurological: watch for acute neurological deficit (stroke/TIA) — cerebral embolism post-DCCV

Patient Safety Post-DCCV

Continue anticoagulation for ≥4 weeks (stunned atrium — no mechanical function despite electrical restoration)
Nil by mouth until fully awake and gag reflex present
No driving for 24 hours post-sedation (GCC licensing requirement)
Responsible adult to accompany patient home
Return if palpitations recur, dyspnoea, or chest pain

Stunned Atrium: After DCCV, the atria regain electrical activity before mechanical function returns (1–4 weeks). Thrombus can still form and embolise even after successful cardioversion. Anticoagulation MUST continue ≥4 weeks minimum regardless of thromboembolic risk.

❌Failed DCCV — Management

Confirm SYNC was active (re-check sync marker)
Check pad-skin contact — re-apply gel if needed; switch to anterior-posterior positioning if using anterior-lateral
Ensure adequate sedation — inadequate sedation increases impedance (muscle tension)
Ensure K⁺, Mg²⁺ corrected before re-attempt
Pre-treat with IV amiodarone 300 mg over 60 min → re-attempt DCCV after loading (increases success rate)
If AF onset clearly <48 hours and patient haemodynamically stable — consider chemical cardioversion (flecainide if no SHD)
Discuss with cardiologist: rhythm control vs rate control acceptance

AF Nurse Specialist Role

👩‍⚕️AF Clinic — Nursing Role

Education

AF mechanism and implications
Stroke risk and anticoagulation rationale
Medication adherence counselling
When and how to seek emergency help
Self-monitoring techniques

Monitoring & Safety

DOAC adherence checks and INR for warfarin
Renal & liver function review (DOAC dose check)
Blood pressure monitoring and targets
Weight monitoring (fluid overload in AF+HF)
Holter monitoring coordination

Coordination

Referrals: electrophysiology, anticoagulation clinic
Symptom tracking: EHRA class trends
Post-ablation follow-up
Telehealth symptom review
AF passport / medication card provision

Lifestyle Modification

🏃Evidence-Based Lifestyle Interventions

Intervention	Evidence	Nursing Counselling Points
Weight Loss	10% weight loss reduces AF burden significantly (LEGACY trial). Obesity is independent risk factor for AF.	Refer to dietitian; set realistic weight goals; BMI <27 kg/m² target; waist circumference monitoring
Alcohol Reduction	HOLIDAY HEART: alcohol acutely triggers AF. >14 units/week increases AF risk 2-fold.	Counsel to reduce/eliminate alcohol; even moderate reduction beneficial; CAGE screening
Exercise	Moderate exercise reduces AF; extreme endurance sport (marathon/triathlon) paradoxically increases AF in men.	Target 150 min/week moderate intensity. Avoid sustained high-intensity exercise >10 h/week.
Treat Obstructive Sleep Apnoea (OSA)	OSA in up to 32% of AF patients; untreated OSA doubles AF recurrence post-ablation.	Screen with STOP-BANG questionnaire; refer for sleep study; CPAP compliance counselling
Hypertension Control	Hypertension: #1 modifiable AF risk factor. BP >130/80 mmHg increases AF risk.	Home BP monitoring; target <130/80 mmHg; medication adherence; low-salt diet

Patient Education

📚When to Seek Emergency Help

CALL EMERGENCY (999/911) IMMEDIATELY:

Sudden severe chest pain
Loss of consciousness / syncope
Signs of stroke: facial droop, arm weakness, slurred speech (FAST)
Severe breathlessness at rest
Severe bleeding while on anticoagulant

CONTACT AF CLINIC / GP SOON:

New palpitations or change in character
Worsening exertional dyspnoea
Pre-syncope / dizziness
Ankle oedema progression
Missed anticoagulant doses (>1 DOAC dose, or INR out of range)
New medication started that may interact

💊DOAC Patient Counselling

Topic	Key Points
Timing adherence	Take at same time each day; set phone alarm. Rivaroxaban must be taken with evening meal for absorption.
Missed dose — BD dosing	If <6 h since scheduled dose: take now. If >6 h: skip and take next dose as scheduled. NEVER double-dose.
Missed dose — OD dosing	If same day: take now. If next day: skip missed dose and continue normal schedule.
Drug interactions (moderate–major)	Azole antifungals (fluconazole, itraconazole): increase DOAC levels significantly. Clarithromycin: inhibits P-gp — increases dabigatran/rivaroxaban. St. John's Wort: reduces all DOAC levels. Rifampicin: major inducer — avoid.
Procedures / surgery	Inform ALL healthcare providers about anticoagulant. Typically hold 24–48 h pre-procedure (48–72 h for dabigatran if CrCl <50). Resume 24–48 h post-procedure when haemostasis achieved.
No INR monitoring	DOACs do not require routine blood monitoring — but renal function (CrCl) should be checked annually (or more if elderly/ill).

🚗Self-Monitoring & Driving

Self-Monitoring Skills

Radial pulse check: 60-second count, note irregularity
Home BP monitoring: log readings, target <130/80
Daily weight (HF patients): alert if >2 kg gain in 2 days
Symptom diary: episode date, duration, symptoms, triggers
Wearable / smartwatch AF detection: share data with clinician

Driving Regulations (GCC)

Post-DCCV: no driving 24 h minimum (sedation effect)
Symptomatic AF with syncope / pre-syncope: refrain from driving until controlled
GCC licensing authorities (UAE RTA / Saudi MOI): cardiovascular clearance may be required for commercial/heavy vehicle drivers
Advise patient to notify insurer of AF diagnosis
Implantable device (pacemaker/ICD): specific driving restrictions apply

AF Epidemiology in GCC

🌍AF Burden in the Gulf Region

Prevalence & Patterns

Hypertension-driven AF is the predominant cause — highest burden in GCC due to high prevalence of uncontrolled hypertension
Rising prevalence with rapid population ageing in Gulf nations
AF occurring in younger GCC patients (40–60 years) — associated with metabolic syndrome, obesity, and diabetes
Higher rates of diabetic cardiomyopathy as AF substrate
Rheumatic heart disease–related AF: still prevalent in South Asian expatriate population in UAE/Qatar

Risk Factor Profile

Obesity rates >40% in adult GCC population — major AF driver
Type 2 diabetes prevalence: highest globally (Saudi Arabia ~18%, UAE ~17%)
OSA: underdiagnosed — sedentary lifestyle, obesity
High dietary sodium intake (traditional cuisine)
Physical inactivity — air-conditioned sedentary culture
Qat chewing (Yemen/Oman): stimulant — associated with AF

Ramadan & Anticoagulation

🌙Managing Anticoagulation During Ramadan

Ramadan fasting presents unique medication timing challenges. DOACs can be safely managed with thoughtful scheduling around Iftar (sunset) and Suhoor (pre-dawn meal).

DOAC	Normal Dosing	Ramadan Strategy	Notes
Apixaban	5 mg BD (every 12 h)	Take at Iftar + Suhoor — maintains 12-hour interval. No dose adjustment needed.	Most convenient for Ramadan — consistent BD dosing
Rivaroxaban	20 mg OD with evening meal	Take with Iftar (largest meal). No change required.	Iftar effectively replaces evening meal — absorption maintained
Edoxaban	60 mg OD	Take at Iftar or Suhoor consistently. Can be taken without food (less food-dependent than rivaroxaban).	Flexible timing; maintain consistent daily time
Dabigatran	150 mg BD	Take at Iftar + Suhoor. Ensure with food or water to reduce GI side effects.	GI symptoms more common when taken fasting — food at Suhoor important
Warfarin	Variable OD	Take at consistent time — typically Iftar. Monitor INR more frequently during Ramadan (dietary changes affect vitamin K intake).	INR may fluctuate due to altered diet; check weekly for first 2 weeks of Ramadan

Halal Status of Blood Thinners: All DOACs and warfarin are permissible (halal) under Islamic jurisprudence when used for medical necessity (darura). Gelatin capsules in some formulations — patients may seek alternatives; apixaban and rivaroxaban tablets contain no animal-derived excipients. Consult pharmacy for capsule composition if required.

Warfarin Challenges in GCC

⚠️Warfarin Management Challenges Specific to GCC

Dietary Vitamin K Variability

Dates: very low vitamin K — mass consumption in Ramadan may affect INR minimally but fibre content can affect GI absorption
Leafy vegetables (molokhia, spinach, parsley, fenugreek): high vitamin K — counsel consistent consumption, not avoidance
Feast days: Eid Al-Fitr / Eid Al-Adha — large dietary changes; INR check recommended after Eid
Traditional dishes: machboos, jareesh, harees — variable vegetable content

Cross-GCC Travel Challenges

INR monitoring services vary between GCC countries — home INR monitoring recommended for frequent travellers
Warfarin brands differ (Coumadin vs Marevan vs local generics) — different binders may slightly affect absorption; recheck INR on brand change
Heat exposure (GCC summer) may increase warfarin sensitivity
Consider DOAC switch for patients with poor TTR or frequent travel
Provide patient anticoagulation passport — accepted at GCC hospitals

GCC Guidelines & Services

📋DHA / MOH AF Management Guidelines

UAE — DHA & DOH Guidelines

DHA (Dubai Health Authority) AF management pathway aligned with ESC 2020 guidelines
DOACs preferred first-line anticoagulant for non-valvular AF
Mandated CHA₂DS₂-VASc documentation in electronic health records
AF nurse-led anticoagulation clinics in DHA facilities (Rashid, Dubai Hospital)
Abu Dhabi DOH: integrated AF care pathway with primary care gatekeeping

Saudi Arabia — MOH Guidelines

Saudi Heart Association (SHA) AF guidelines 2021 — ESC-aligned
National Unified Formulary (NUF): DOACs on approved list
King Fahad Medical City, King Abdulaziz Medical City (KAMC): dedicated electrophysiology units
DCCV and AF ablation available at all tertiary centres (Riyadh, Jeddah, Dammam)
Anticoagulation clinics expanding to primary care / polyclinics

Qatar — MOPH / HMC

Hamad Medical Corporation: advanced EP programme
DCCV performed at Heart Hospital Doha
National Cardiovascular Prevention Programme integrates AF screening

Kuwait & Bahrain

Chest Disease Hospital (Kuwait): AF electrophysiology
Ministry of Health Kuwait: anticoagulation clinic network
Bahrain Defence Force Hospital: DCCV and ablation services

Oman

Royal Hospital Muscat: tertiary EP centre
MOH Oman: DCCV available at secondary level hospitals
Active nurse-led follow-up clinics in polyclinics

Emerging AF Nurse Specialist Role in GCC

⭐AF Nurse Specialist — GCC Development

Current Status

AF nurse specialist role emerging — modelled on UK Heart Rhythm Nurse
UAE: DHA Advanced Practice Nurse (APN) pathway supports specialist development
Saudi Arabia: Saudi Commission for Health Specialties (SCFHS) recognises cardiovascular nursing specialty
Nurse-led DOAC clinics reducing physician burden in UAE and Qatar
Telemedicine AF monitoring — nurses conducting virtual follow-up consultations

Key Competencies for GCC AF Nurse

12-lead ECG interpretation including AF recognition
CHA₂DS₂-VASc / HAS-BLED calculation and clinical application
DOAC and warfarin counselling including Ramadan management
DCCV pre/post-procedure nursing care
Cultural competence: Ramadan, halal medications, dietary norms
Arabic patient education — multilingual AF education materials
OSA screening and CPAP compliance support
Digital health tools: wearable AF device interpretation

Professional Development: GCC AF nurses are encouraged to pursue BHRS (British Heart Rhythm Society) Heart Rhythm Nurse accreditation, ACNAP (ESC) Heart Failure / Arrhythmia nurse certification, and regional Gulf Heart Association (GHA) CME activities for AF management.

📞Emergency Contacts & Resources

Emergency Numbers

UAE: 998 (ambulance)
Saudi Arabia: 911
Qatar: 999
Kuwait: 112
Bahrain: 999
Oman: 9999

AF Patient Resources

AliveCor / KardiaMobile: portable ECG for AF self-detection
Apple Watch Series 4+ : FDA-cleared AF detection
Anticoagulation Europe: patient information
GHA (Gulf Heart Association): patient education materials

Clinical Resources

ESC 2020 AF Guidelines (van Gelder et al.)
ESC 2023 AF update
AF-CARE pathway (ESC)
SHA AF Guidelines 2021
DHA Clinical Practice Guidelines